Xencor, Inc Debt Securities, Available-for-sale, Gain (Loss)
Xencor, Inc (XNCR) reported Debt Securities, Available-for-sale, Gain (Loss) of -$2.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleGainLoss · last filed 2026-08-05
- Xencor, Inc debt securities, available-for-sale, gain (loss) for the quarter ending 2025-12-31 was $9.41M, a 27591.18% increase year-over-year.
- Xencor, Inc debt securities, available-for-sale, gain (loss) for the quarter ending 2025-09-30 was -$407.00K.
- Xencor, Inc debt securities, available-for-sale, gain (loss) for the quarter ending 2025-06-30 was $5.38M.
- Xencor, Inc debt securities, available-for-sale, gain (loss) for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Xencor, Inc debt securities, available-for-sale, gain (loss) for fiscal 2025 was $14.39M, a 38786.49% increase from fiscal 2024.
- Xencor, Inc debt securities, available-for-sale, gain (loss) for fiscal 2024 was $37.00K.
- Xencor, Inc debt securities, available-for-sale, gain (loss) for fiscal 2023 was $0.00.
| Period end | Debt Securities, Available-for-sale, Gain (Loss) 3 month | Debt Securities, Available-for-sale, Gain (Loss) 6 month | Debt Securities, Available-for-sale, Gain (Loss) 9 month | Debt Securities, Available-for-sale, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.01M derived: sum of 2 quarters · filed 2026-02-25 | $14.39M derived: sum of 3 quarters · filed 2026-08-05 | $14.39M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$407.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.97M derived: sum of 2 quarters · filed 2026-08-05 | $4.97M 10-Q · filed 2025-11-05 | $5.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.38M 10-Q · filed 2026-08-05 | $5.41M derived: sum of 3 quarters · filed 2026-08-05 | $5.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $34.00K derived: sum of 2 quarters · filed 2026-02-25 | $34.00K derived: sum of 3 quarters · filed 2026-02-25 | $34.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $34.00K derived: sum of 2 quarters · filed 2026-02-25 | $34.00K derived: sum of 3 quarters · filed 2026-02-25 | $37.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $3.00K 10-Q · filed 2025-11-05 | $3.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.00K 10-Q · filed 2025-08-06 | $3.00K derived: sum of 3 quarters · filed 2026-02-25 | $3.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.00K 10-Q · filed 2025-05-07 | $3.00K derived: sum of 2 quarters · filed 2026-02-25 | $3.00K derived: sum of 3 quarters · filed 2026-02-25 | $3.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | |
| 2023-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |